Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anacetrapib add-on therapy in adults with homozygous familial hypercholesterolemia
2012-002434-37Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anacetrapib in homozygous familial hypercholesterolemia (HoFH) (3 arms), sponsored by Merck & Co. Primary endpoint: Percent change in LDL-C from baseline to week 12. Started Nov 2012; status: terminated.
02
Drugs
anacetrapib
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on 2012-002434-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002434-37.